EPO and coronary artery disorder: For instance, hemoglobin level was significantly increased by administration of empagliflozin, accompanied by increased erythropoietin levels and reduced serum ferritin in type 2 DM patients with coronary artery disease in the EMPA-HEART CardioLink-6 randomized clinical trial [28, 29].